TREM1 and neoplasm: Recently, experimental and human studies have suggested that TREM-1 pharmacologic targeting may represent a potential novel therapeutic modality to inhibit MP-mediated chronic inflammation-associated tumor development, pointing to TREM-1 as an attractive new immunotherapeutic target also for cancer [37,157] (Figure 2, Table 2).